uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted September 2, 2016

Kratom To Be Classified a Schedule I Controlled Substance

On August 30, 2016, the U.S. Drug Enforcement Agency (DEA) announced its intent to classify the active compounds (mitragynine and 7-hydroxymitragynine) in kratom as Schedule I controlled substances.  

Kratom (Mitragyna speciosa), also called mitragynine extract, biak-biak, cratom, gratom, ithang, kakuam, katawn, kedemba, ketum, krathom, krton, mambog, madat, Maeng da leaf, nauclea, Nauclea speciosa, or thang is a tree native to Southeast Asia. Supplements containing kratom typically contain powdered leaves or extract sold in powder, capsules or liquid, and are promoted for pain relief or energy.

The active compounds in kratom are opioids which can have effects similar to morphine and heroin. Consumption of kratom has been associated with agitation, irritability, tachycardia, nausea, drowsiness, and hypertension. Health risks found in kratom abusers include hepatotoxicity, psychosis, seizure, weight loss, insomnia, tachycardia, vomiting, poor concentration, hallucinations, and death. The agency stated it is aware of 15 kratom-related deaths between 2014 and 2016.

Other Schedule I controlled substances include heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.

U.S. Marshals have seized hundreds of thousands of dollars' worth of kratom supplements since that the FDA issued an import alert on all products containing kratom in 2014.

See Related Warnings:

U.S. Marshals Seize $150,00 Worth of Kratom

Over $400,000 Worth of Kratom Supplements Seized by U.S. Marshals

U.S. Marshals Seize $5 Million Worth of Kratom

Products Containing Kratom Recalled Following FDA Import Alert

$2 Million In Weight Loss and "Fat-Burning" Supplements Seized

FDA Seizes Weight Loss Supplements Containing Undeclared Drug

FDA Requests Seizure of More Supplements Containing Ephedrine Alkaloids

To read the DEA's press release, use the link below.